ORATOR II
02 Dec 2020
Trial Summary
The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary surgical approach, to provide a high level of evidence to guide the selection of treatment options for a subsequent phase III trial.
Acronym:
ORATOR II
ACTRN/NCT /ethics:
NCT03210103
Scientific title:
A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)
Sponsor / Cooperative group:
London Regional Cancer Program
Trial & Patient Characteristics
| Cancer Type | Head and Neck |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Oropharyngeal Squamous Cell Carcinoma |
| Cancer Stage | All stages |
| Anticipated Start Date | 2018-01-26 |
| Anticipated End Date | 2028-08-15 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Dr Surendranath Krishnan |
| Recruitment Status | Recruiting |